• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Inovio Pharmaceuticals Inc.

    2/10/25 5:06:11 PM ET
    $INO
    Medical/Dental Instruments
    Health Care
    Get the next $INO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Inovio Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    45773H409

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45773H409


    1Names of Reporting Persons

    Highbridge Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,633,333.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,633,333.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,633,333.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.2 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Includes 3,333,333 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Inovio Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Inovio Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), directly held, and issuable upon exercise of warrants directly held, by the Highbridge Funds. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.
    (c)Citizenship:

    Highbridge is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    45773H409
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 36,052,452 shares of Common Stock outstanding immediately after giving effect to the completion of the Issuer's underwritten public offering, as described in the Issuer's prospectus supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on December 13, 2024, and assumes the exercise of the warrants held by the Highbridge Funds.
    (b)Percent of class:

    9.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Highbridge Capital Management, LLC
     
    Signature:/s/ Kirk Rule
    Name/Title:Kirk Rule, Executive Director
    Date:02/10/2025
    Get the next $INO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INO

    DatePrice TargetRatingAnalyst
    5/14/2024$20.00Overweight
    Stephens
    1/25/2024$4.00Perform → Outperform
    Oppenheimer
    11/9/2022Buy → Hold
    Maxim Group
    11/1/2022$2.00Neutral → Underperform
    BofA Securities
    7/19/2022$5.00 → $4.00Sector Perform
    RBC Capital Mkts
    5/11/2022Outperform → Perform
    Oppenheimer
    3/2/2022$6.00 → $5.00Sector Perform
    RBC Capital
    1/21/2022$8.00 → $10.00Underperform → Neutral
    B of A Securities
    More analyst ratings

    $INO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on Inovio Pharma with a new price target

      Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00

      5/14/24 8:01:14 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Inovio Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00

      1/25/24 7:27:17 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Inovio Pharma downgraded by Maxim Group

      Maxim Group downgraded Inovio Pharma from Buy to Hold

      11/9/22 9:19:58 AM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Financials

    Live finance-specific insights

    See more
    • INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

      PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.in

      4/29/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the yearAnnounced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86

      3/18/25 4:05:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

      PLYMOUTH MEETING, Pa., March 12, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that fourth quarter and year-end 2024 financial results will be released after the market close on March 18, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online

      3/12/25 12:55:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $INO
    SEC Filings

    See more
    • Chief Scientific Officer Humeau Laurent converted options into 8,865 shares and covered exercise/tax liability with 3,643 shares, increasing direct ownership by 21% to 29,559 units (SEC Form 4)

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      2/28/25 6:06:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Chief Medical Officer Sumner Michael John converted options into 5,010 shares, increasing direct ownership by 61% to 13,229 units (SEC Form 4)

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      2/28/25 6:05:49 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Shea Jacqueline Elizabeth converted options into 24,484 shares and covered exercise/tax liability with 11,581 shares, increasing direct ownership by 38% to 46,550 units (SEC Form 4)

      4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

      2/28/25 6:05:39 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Inovio Pharmaceuticals Inc.

      SCHEDULE 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      4/30/25 11:24:07 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Inovio Pharmaceuticals Inc.

      SCHEDULE 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      4/17/25 9:35:29 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Inovio Pharmaceuticals Inc.

      DEF 14A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

      4/7/25 4:08:23 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Inovio Pharmaceuticals Inc.

      SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      4/26/24 4:01:17 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      1/22/24 10:20:28 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

      SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

      7/10/23 2:07:33 PM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INOVIO to Present at Upcoming Scientific and Investor Conferences

      PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM), the largest meeting of otolaryngologists in the U.S.

      4/30/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025

      PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.in

      4/29/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO to Present at Upcoming Scientific Conferences

      PLYMOUTH MEETING, Pa., April 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will highlight key data associated with its lead candidate, INO-3107, at several upcoming conferences, including an opportunity to join other leading voices at the inaugural National HPV Conference. INOVIO will also discuss its novel DNA-encoded monoclonal antibody technology at a preconference workshop at the World Vaccine Congress.

      4/9/25 8:05:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care

    $INO
    Leadership Updates

    Live Leadership Updates

    See more
    • INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

      PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for pati

      1/9/25 8:04:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

      Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le

      7/2/24 4:05:00 PM ET
      $INO
      Medical/Dental Instruments
      Health Care
    • INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

      PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO's clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. He will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Offic

      6/27/22 8:00:00 AM ET
      $INO
      Medical/Dental Instruments
      Health Care